ClinicalTrials.Veeva

Menu
I

Inselspital | Universitatsklinik Inselspital Bern - Gastroenterologie

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

Durvalumab
Atezolizumab
Rivaroxaban
Lenalidomide
Gemcitabine
Panitumumab
Capecitabine
Pregabalin
Velcade
GDC-6036

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

6 of 123 total trials

A Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-6036 Alone or in Combination in Participants With Advanced or Metastatic Solid Tumors With a KRAS G12C Mutation

This is a Phase I dose-escalation and dose-expansion study that will evaluate the safety, pharmacokinetics (PK), and preliminary activity of GDC-6036...

Enrolling
Advanced Solid Tumors
Colorectal Cancer
Drug: Inavolisib
Drug: Atezolizumab

Some patients with limited disease small-cell lung cancer (LD SCLC) are cured after chemo-radiotherapy, but the majority relapse and die from their c...

Active, not recruiting
Small-cell Lung Cancer
Drug: Atezolizumab

Atezolizumab is an engineered humanised monoclonal immunoglobulin G1 antibody that binds selectively to PD-L1 and prevents its interaction with PD-1...

Active, not recruiting
Endometrial Cancer
Drug: Placebos
Drug: Atezolizumab

The Revita® system is being investigated to assess the efficacy of DMR versus Sham on improvement in Glycemic, Hepatic and Cardiovascular endpoints f...

Enrolling
Type 2 Diabetes
Device: Duodenal Mucosal Resurfacing (Sham)
Device: Duodenal Mucosal Resurfacing (DMR)

This is a multicenter, randomized, open-label, Phase 3 study in participants with newly diagnosed multiple myeloma to evaluate the benefits of teclis...

Enrolling
Multiple Myeloma
Drug: Lenalidomide
Drug: Teclistamab

Prospective, multicenter, single-arm, open label, interventional study evaluating adoptive cell therapy (ACT) with autologous tumor infiltrating lymp...

Active, not recruiting
Cervical Carcinoma
Biological: LN-145 + pembrolizumab
Biological: LN-145

Trial sponsors

I
E
S
University Hospitals (UH) logo
S
University Hospital Basel logo
F
C
Edwards Lifesciences logo
I

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems